The Effect of Orally Dosed Levagen+™ (palmitoylethanolamide) on Exercise Recovery in Healthy Males—A Double-Blind, Randomized, Placebo-Controlled Study
Randomised controlled trialHumans
- Design
- Randomised controlled trial
- Subjects
- 28 healthy young men. All completed.
- Dose used in the study
- 167.5 mg of Levagen+ (150 mg of palmitoylethanolamide) as a drink, before exercise, after exercise, and at 24 and 48 hours
- Duration
- Four laboratory visits over consecutive days
- What was measured
- Muscle soreness, thigh circumference, blood lactate, markers of muscle damage and markers of inflammation
What the authors reported
The trial found:
- Lower myoglobin at 1, 2 and 3 hours after exercise and lower blood lactate at 1 and 3 hours in the Levagen+ group, alongside increased protein kinase B phosphorylation.
- No difference between groups in muscle soreness or thigh circumference.
- No adverse effects were reported.
Limits of this study
A small study in healthy young men over a few days. The differences were in blood markers. The outcomes a person would notice, soreness and swelling, did not differ. The study was funded by Gencor Pacific.
Source
PubMed 32106527 · doi:10.3390/nu12030596
Entry checked against the abstract on PubMed, and the full text at the publisher (MDPI) on 2026-10-19. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.